Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?

Bernardo Stefanini; Matteo Tonnini; Mariarosaria Marseglia; Francesco Tovoli

doi:10.1080/14737140.2022.2105210

Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?

Expert Rev Anticancer Ther. 2022 Sep;22(9):887-889. doi: 10.1080/14737140.2022.2105210. Epub 2022 Jul 26.

Authors

Bernardo Stefanini^{1

2}, Matteo Tonnini^{1

2}, Mariarosaria Marseglia¹, Francesco Tovoli^{1

2}

Affiliations

¹ Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Italy.
² Department of Medical and Surgical Sciences, University of Bologna, Bologna Italy.

PMID: 35866267
DOI: 10.1080/14737140.2022.2105210

No abstract available

Keywords: Aspirin; biliary tract cancer; chemoprevention; cholangiocarcinoma; cirrhosis; hemostasis; hepatocellular carcinoma; liver cancer; outcome.

Publication types

Editorial

MeSH terms

Aspirin
Bile Duct Neoplasms* / drug therapy
Bile Duct Neoplasms* / pathology
Bile Ducts, Intrahepatic / pathology
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Cholangiocarcinoma* / drug therapy
Cholangiocarcinoma* / pathology
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Prognosis

Substances

Aspirin